News | December 18, 2023
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
10+ emerging markets, Japan & ANZ transition in final phase
10+ emerging markets, Japan & ANZ transition in final phase
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
Expands patient reach to remotest towns by furthering investment in GoApptiv
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
Demonstrate significant bleed reduction in hemophilia A and B
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Express Scripts to add Zepbound to National Preferred Formulary
Subscribe To Our Newsletter & Stay Updated
